Race for coronavirus treatment - As the global race continues to try and find a treatment for coronavirus the UK biotech firm Synairgen is reportedly planning to trial its experimental lung drug on Covid-19 patients.
The company received the green light from UK regulators to conduct a trial of its lead drug SNG001 at NHS trusts across the country.
The inhaled drug has been in development as a treatment for chronic-obstructive pulmonary disorder (COPD), a severe lung disease, but this has been paused to conduct testing on 100 patients who have been diagnosed with Covid-19.
It was identified in a WHO analysis of potential treatments against the coronavirus. Patients can self-administer it, through a small hand-held battery-operated nebulizer.
The trial is due to start next week.
Cafe and restaurants owners in the Alpes Maritimes are to meet with the prefect today ahead of the possible closure of their establishments at 10pm du... Read More